SSYS vs DSGN Comparison

Stratasys Ltd offers polymer-based 3D printing solutions for designers, engineers, manufacturers, dental and medical professionals, and others. Its 3D printing systems utilize the firm's patented extrusion-based FDM, inkjet-based PolyJet, powder-bed-based SAF, photopolymer-based P3, and Neo stereolithography technologies to enable the production of prototypes, tools, and manufactured goods directly from 3D CAD files or other 3D content. The company's solutions portfolio comprises 3D printing systems, consumables, software, paid parts, and professional services, allowing end-users to effectively print 3D models, tools, and parts. Geographically, it generates maximum revenue from the United States, followed by Europe, Middle East and Africa, Asia-Pacific, and other regions.

Design Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the research and development of GeneTAC molecules, which are a novel class of small-molecule gene targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. Its pipeline includes Friedreich Ataxia, FECD, DM1, and Huntington's Disease. The company operates in one operating and reportable segment focused on utilizing the company's proprietary GeneTAC platform to design and develop therapeutic candidates for inherited diseases driven by nucleotide repeat expansion.